Radotinib

Systematic (IUPAC) name
4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide
Clinical data
Trade names	Supect
Identifiers
CAS Registry Number	926037-48-1
PubChem	CID 16063245
ChemSpider	17222861
Chemical data
Formula	C27H21F3N8O
Molecular mass	530.50 g/mol
SMILES CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=NC=CN=C5
InChI InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37) Key:DUPWHXBITIZIKZ-UHFFFAOYSA-N

Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML)^[1] with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors, such as patients resistant or intolerant to the drug Imatinib (Gleevec, Glivec).

Radotinib is being developed by Ilyang Pharmaceutical Co., Ltd of South Korea^[2] and is co-marketed by Daewoong Pharmaceutical Co. Ltd, in South Korea.^[3] Radotinib completed a multi-national Phase II clinical trial study in 2012^[4] and in August 2011, Ilyang initiated a Phase III, multinational, multi-center, open-label, randomized study for first-line indication.^[5] Its mechanism of action involves inhibition of the tyrosine kinase Bcr-Abl and of platelet-derived growth factor receptor (PDGFR).^[6]

References